Nutriband Inc. (NASDAQ:NTRB - Get Free Report) traded up 1.7% on Thursday . The stock traded as high as $7.86 and last traded at $7.83. 21,051 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 80,500 shares. The stock had previously closed at $7.70.
Nutriband Price Performance
The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.48 and a current ratio of 3.71. The company has a fifty day moving average price of $6.50 and a two-hundred day moving average price of $6.09. The company has a market cap of $88.98 million, a P/E ratio of -8.87 and a beta of 1.11.
Nutriband (NASDAQ:NTRB - Get Free Report) last posted its quarterly earnings results on Friday, May 30th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. Nutriband had a negative return on equity of 68.25% and a negative net margin of 415.93%. The firm had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.71 million. On average, sell-side analysts anticipate that Nutriband Inc. will post -0.6 earnings per share for the current fiscal year.
Institutional Trading of Nutriband
Several institutional investors and hedge funds have recently added to or reduced their stakes in NTRB. Geode Capital Management LLC increased its stake in shares of Nutriband by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 62,435 shares of the company's stock worth $294,000 after purchasing an additional 4,372 shares during the last quarter. Haven Private LLC bought a new position in Nutriband during the fourth quarter worth about $54,000. Finally, US Bancorp DE bought a new position in Nutriband during the first quarter worth about $29,000. 19.70% of the stock is owned by institutional investors.
Nutriband Company Profile
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
See Also
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
